Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis
Copyright © 2023 Elsevier Ltd. All rights reserved..
INTRODUCTION: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) improves CFTR function in cystic fibrosis (CF) patients homozygous or heterozygous for F508del mutation. The aim of the study was to evaluate the response to ELX/TEZ/IVA treatment both clinically and morphologically in terms of bronchiectasis, bronchial wall thickening, mucus plugging, abscess and consolidations.
METHODS: We retrospectively collected data from CF patients followed at Parma CF Centre (Italy) treated by ELX/TEZ/IVA between March and November 2021. Post-treatment changes in respiratory function, quality of life, sweat chloride concentration, body mass index, pulmonary exacerbations and lung structure by chest magnetic resonance imaging (MRI) were assessed. T2-and T1-weighted sequences were acquired with a 20 min-long scanning protocol on a 1.5T MRI scanner (Philips Ingenia) without administration of intravenous contrast media.
RESULTS: 19 patients (32.5 ± 10.2 years) were included in the study. After 6 months of treatment with ELX/TEZ/IVA, MRI showed significant improvements in the morphological score (p < 0.001), with a reduction in bronchial wall thickening (p < 0.001) and mucus plugging (p 0.01). Respiratory function showed significant improvement in predicted FEV1% (58.5 ± 17.5 vs 71.4 ± 20.1, p < 0.001), FVC% (79.0 ± 11.1 vs 88.3 ± 14.4, p < 0.001), FEV1/FVC (0.61 ± 0.16 vs 0.67 ± 0.15, <0.001) and LCI2.5% (17.8 ± 4.3 vs 15.8 ± 4.1 p < 0.005). Significant improvement was found in body mass index (20.6 ± 2.7 vs 21.9 ± 2.4, p < 0.001), pulmonary exacerbations (2.3 ± 1.3 vs 1.4 ± 1.3 p 0.018) and sweat chloride concentration (96.5 ± 36.6 vs 41.1 ± 16.9, p < 0.001).
CONCLUSIONS: Our study confirms the efficacy of ELX/TEZ/IVA in CF patients not only from a clinical point of view but also in terms of morphological changes of the lungs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:216 |
|---|---|
| Enthalten in: |
Respiratory medicine - 216(2023) vom: 15. Sept., Seite 107328 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fainardi, Valentina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1Y740ILL1Z |
|---|
| Anmerkungen: |
Date Completed 12.07.2023 Date Revised 18.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmed.2023.107328 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358229022 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358229022 | ||
| 003 | DE-627 | ||
| 005 | 20231226074311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rmed.2023.107328 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358229022 | ||
| 035 | |a (NLM)37321310 | ||
| 035 | |a (PII)S0954-6111(23)00216-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fainardi, Valentina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) improves CFTR function in cystic fibrosis (CF) patients homozygous or heterozygous for F508del mutation. The aim of the study was to evaluate the response to ELX/TEZ/IVA treatment both clinically and morphologically in terms of bronchiectasis, bronchial wall thickening, mucus plugging, abscess and consolidations | ||
| 520 | |a METHODS: We retrospectively collected data from CF patients followed at Parma CF Centre (Italy) treated by ELX/TEZ/IVA between March and November 2021. Post-treatment changes in respiratory function, quality of life, sweat chloride concentration, body mass index, pulmonary exacerbations and lung structure by chest magnetic resonance imaging (MRI) were assessed. T2-and T1-weighted sequences were acquired with a 20 min-long scanning protocol on a 1.5T MRI scanner (Philips Ingenia) without administration of intravenous contrast media | ||
| 520 | |a RESULTS: 19 patients (32.5 ± 10.2 years) were included in the study. After 6 months of treatment with ELX/TEZ/IVA, MRI showed significant improvements in the morphological score (p < 0.001), with a reduction in bronchial wall thickening (p < 0.001) and mucus plugging (p 0.01). Respiratory function showed significant improvement in predicted FEV1% (58.5 ± 17.5 vs 71.4 ± 20.1, p < 0.001), FVC% (79.0 ± 11.1 vs 88.3 ± 14.4, p < 0.001), FEV1/FVC (0.61 ± 0.16 vs 0.67 ± 0.15, <0.001) and LCI2.5% (17.8 ± 4.3 vs 15.8 ± 4.1 p < 0.005). Significant improvement was found in body mass index (20.6 ± 2.7 vs 21.9 ± 2.4, p < 0.001), pulmonary exacerbations (2.3 ± 1.3 vs 1.4 ± 1.3 p 0.018) and sweat chloride concentration (96.5 ± 36.6 vs 41.1 ± 16.9, p < 0.001) | ||
| 520 | |a CONCLUSIONS: Our study confirms the efficacy of ELX/TEZ/IVA in CF patients not only from a clinical point of view but also in terms of morphological changes of the lungs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a ELX/TEZ/IVA | |
| 650 | 4 | |a Lung structure | |
| 650 | 4 | |a MRI | |
| 650 | 4 | |a Modulators | |
| 650 | 4 | |a Mucus plugging | |
| 650 | 7 | |a elexacaftor |2 NLM | |
| 650 | 7 | |a RRN67GMB0V |2 NLM | |
| 650 | 7 | |a ivacaftor |2 NLM | |
| 650 | 7 | |a 1Y740ILL1Z |2 NLM | |
| 650 | 7 | |a tezacaftor |2 NLM | |
| 650 | 7 | |a Chlorides |2 NLM | |
| 700 | 1 | |a Skenderaj, Kaltra |e verfasserin |4 aut | |
| 700 | 1 | |a Ciuni, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Milanese, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Deolmi, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Longo, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Spaggiari, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Sverzellati, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Pisi, Giovanna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory medicine |d 1993 |g 216(2023) vom: 15. Sept., Seite 107328 |w (DE-627)NLM012605247 |x 1532-3064 |7 nnns |
| 773 | 1 | 8 | |g volume:216 |g year:2023 |g day:15 |g month:09 |g pages:107328 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmed.2023.107328 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 216 |j 2023 |b 15 |c 09 |h 107328 | ||